Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde

Clinical Chemistry

Volumn 56, Issue 5, 2010, Pages 832-838

  Holmes, Courtney ^a   Whittaker, Noel ^b   Heredia Moya, Jorge ^b   Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; ACETIC ACID; ALDEHYDE DERIVATIVE; NORADRENALIN; PHOSPHORIC ACID; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CENTRIFUGATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CONTAMINATION; DRUG METABOLISM; ELECTROCHEMICAL DETECTION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE;

3,4-DIHYDROXYPHENYLACETIC ACID; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHROMATOGRAPHY, LIQUID; DROXIDOPA; DRUG CONTAMINATION; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 77951749932     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.139709     Document Type: Article

References (13)

1. Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724-728 (Pubitemid 36999258)
2. Blaschko H, Burn JH, Langemann H. The formation of noradrenaline from dihydroxyphenylserine. Br J Pharmacol Chemother 1950;5:431-437
3. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 2004;25:101-115
4. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3,4- Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 2003;989:205-213
5. Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14:363-368 (Pubitemid 40193023)
6. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatog B Biomed Applic 1994;653:131-138 (Pubitemid 24085051)
7. Blaschko H. Amine oxidase and amine metabolism. Pharmacol Rev 1952;4:415-458
8. Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 1995;4:271-281
9. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, Burke WJ. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 2001;30:924-931
10. Legros H, Janin F, Dourmap N, Bonnet JJ, Costentin J. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. J Neurosci Res 2004;75:429-435 (Pubitemid 38173479)
11. Legros H, Dingeval MG, Janin F, Costentin J, Bonnet JJ. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 2004;25:365-375 (Pubitemid 38283541)
12. 2+-independent mechanism. Brain Res 2002;931:96-99
13. Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008;115:193-203.